June 5 (Reuters) - Amgen Inc AMGN.O :
* AMGEN HIGHLIGHTS VERSATILITY OF BITE® IMMUNO-ONCOLOGY PLATFORM IN MULTIPLE TUMOUR TYPES AT ASCO 2019
* AS OF LATEST READOUT, AMG 420 INDUCED CLINICAL RESPONSES IN 13 OF 42 PATIENTS ACROSS DOSING COHORTS
* AMGEN INC - SERIOUS ADVERSE EVENTS (AES) WERE REPORTED IN 19 PATIENTS (45 PERCENT) IN AMG 420 STUDY